Veenhuizen, Stefanie G. A.
van Grinsven, Sophie E. L.
Laseur, Isabelle L.
Bakker, Marije F.
Monninkhof, Evelyn M.
de Lange, Stéphanie V.
Pijnappel, Ruud M.
Mann, Ritse M.
Lobbes, Marc B. I.
Duvivier, Katya M.
de Jong, Mathijn D. F.
Loo, Claudette E.
Karssemeijer, Nico
van Diest, Paul J.
Veldhuis, Wouter B.
van Gils, Carla H.
van Gils, C H
Bakker, M F
van Grinsven, S E L
de Lange, S V
Veenhuizen, S G A
Veldhuis, W B
Pijnappel, R M
Emaus, M J
Monninkhof, E M
Fernandez-Gallardo, M A
van den Bosch, M A A J
van Diest, P J
Mann, R M
Mus, R
Imhof-Tas, M
Karssemeijer, N
Loo, C E
de Koekkoek-Doll, P K
Winter-Warnars, H A O
Bisschops, R H C
Kock, M C J M
Storm, R K
van der Valk, P H M
Lobbes, M B I
Gommers, S
Lobbes, M B I
de Jong, M D F
Rutten, M J C M
Duvivier, K M
de Graaf, P
Veltman, J
Bourez, R L J H
de Koning, H J
,
Funding for this research was provided by:
Universitair Medisch Centrum Utrecht (UMCU DENSE)
ZonMw (ZONMW-200320002-UMCU, ZonMW Preventie 50-53125-98-014)
KWF Kankerbestrijding (DCS-UU-2009-4348, UU-2014-6859, UU-2014-7151)
Stichting A Sister's Hope (Pink Ribbon-10074)
Pharmaceuticals Bayer (BSP-DENSE)
Stichting Kankerpreventie Midden-West
Volpara Health Technologies
Article History
Received: 29 June 2023
Revised: 19 January 2024
Accepted: 3 February 2024
First Online: 19 April 2024
Declarations
:
: The scientific guarantor of this publication is Carla van Gils.
: The authors of this manuscript declare relationships with the following companies: Siemens Healthineers (R.M.), Koning (R.M.), PA imaging (R.M.), Screenpoint medical (R.M., N.K.), BD (R.M.), Micrima (R.M.), Volpara Health Care ltd (R.M.), QView Medical Inc (N.K.), Samantree (P.v.D), Sectra (P.v.D.), Visiopharm (P.v.D.), Paige (P.v.D). R.M. is a member of the <i>European Radiology</i> Advisory Editorial Board (European Society of Breast Imaging), and they have not taken part in the review or selection process of this article. The remaining authors declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional review board approval was obtained.
: The trial participants and other trial outcomes have been described earlier:1. Bakker MF, de Lange SV, Pijnappel RM et al (2019) Supplemental MRI screening for women with extremely dense breast tissue. <i>New England Journal of Medicine</i> <i>381</i>.22:2091–21022. De Lange SV, Bakker MF, Monninkhof EM et al (2018) Reasons for (non) participation in supplemental population-based MRI breast screening for women with extremely dense breasts. <i>Clinical Radiology</i> <i>73</i>.8:759-e1.3. Veenhuizen SG, de Lange SV, Bakker MF et al (2021) Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. <i>Radiology</i> <i>299</i>.2:278–286.The outcomes related to participation in the second and third screening round of DENSE have not been published before.
: • prospective• randomised controlled trial• multicentre study